Form 4: Axogen Director Sells Shares Under 10b5-1 Plan

Axogen Director William P. Burke sold 1,457 shares of common stock for a weighted average price of $18.018 per share on October 22, 2025, pursuant to a pre-arranged trading plan.

Summary

• William P. Burke, a Director of Axogen, Inc. (AXGN), reported the sale of 1,457 shares of common stock.
• The transaction occurred on October 22, 2025, at a weighted average price of $18.018 per share.
• The shares were sold in multiple transactions at prices ranging from $18.00 to $18.045 per share.
• This sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on March 14, 2025.
• Following this transaction, Mr. Burke beneficially owns 100 shares of Axogen, Inc. common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider sale of a relatively small number of shares, which is generally considered neutral in terms of market sentiment. The existence of a 10b5-1 plan mitigates any immediate negative interpretation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider trading report is specific to Axogen, Inc. and its director, William P. Burke. It does not provide information directly related to broader industry trends or competitors, beyond the general context of a publicly traded company in the healthcare or medical device sector.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small volume of shares sold and the pre-planned nature of the transaction, which reduces the likelihood of signaling negative insider sentiment.
• Employees, Customers, Suppliers, Creditors: No discernible impact from this specific insider trading report.

Key Dates

Keywords

Axogen, AXGN, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction